Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals — Merger or Acquisition (March 2024)

24 slides from Fusion Pharmaceuticals's merger presentation, Mar 19, 2024

  1. Slide 1: Additional information and where to find it

    Additional information and where to find it In connection with the proposed transaction, Fusion intends to file a proxy circular with the Securities and Exchange Commission (SEC). INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY CIRCULAR IN ITS ENTIRETY IF AND WHEN IT BECOMES AVAILABLE AND

  2. Slide 2: Participants in the solicitation

    Participants in the solicitation This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication is not a substitute for any circular Fusion may file wth the SEC in connection w

  3. Slide 3: Forward looking statements

    Forward looking statements This document may include statements that are not statements of historical fact, or “forward-looking statements,” including with respect to the proposed acquisition of Fusion by AstraZeneca. Such forward looking statements include, but are not limited to, the ability of As

  4. Slide 4: Introduction to Susan Galbraith and Puja Sapra

    Introduction to Susan Susan Galbraith Puja Sapra Executive Vice President Senior Vice President Oncology R&D Biologics Engineering & Oncology Targeted Delivery 6~ STRICTLY CONFIDENTIAL

  5. Slide 5: Pascal Video

    Pascal Video

  6. Slide 6: Our purpose

    Our purpose We push the boundaries of science to deliver life-changing medicines Our strategy Science and Patient-focused Leading in our Diversified Positively innovation-led therapy areas portfolio and impacting people, * Oncology global reach society and * BioPharmaceuticals (R&I, CVRM, V&l) the p

  7. Slide 7: Driving strong growth across geographies and therapy areas

    Driving strong growth across geographies and therapy areas Broad-based, diverse source of Total Revenue FY 2023 | % Total Revenue by therapy area vam Ral V&l Other Rare Disease 239% lee 3% FY 2023 | % Total Revenue by geography us Emer jarkets Europe === EROW Strength across therapy areas FY 2023 |

  8. Slide 8: Investing in new launches, near and mid-term pipeline

    Investing in new launches, near and mid-term pipeline 24 Phase Ill trials initiated across 18 medicines Phase Ill trials initiated with blockbuster potential regulatory approvals in major markets 4. As of E2023. 2.Approvalssince Ol January 2023 throughand up toO7 February 2024 4 NMEs approved? and o

  9. Slide 9: Investing in new platforms and technologies

    Investing in new platforms and technologies Shaping the future of medicine Foundation in ADCs Six wholly owned ADCs — Combo opportunities © Daiichi-Sankyo unique targets end warheads + bispecifics, + CTx Cy Internal technologies neosgene Qauell.. cellectis @eoucee Internal Ancora Biotech HARBOUR Onc

  10. Slide 10: Global reach and presence

    Global reach and presence * Sglobal R&D centres +5 other R&D centres with discovery research labs = 27 manufacturing sitesin 16 countries Gothenburg Employees by reporting region Established Rest of the World y I Emerging Markets: Europe

  11. Slide 11: Our Oncology R&D strategy to transform cancer outcomes

    Our Oncology R&D strategy to transform cancer outcomes Attacking cancer 2 . Treating from multiple angles. earlier and smarter... TODAY Death Data and Al: Inform trials, speed recruitment, better models + treatment ‘TUMOUR BURDEN Computational HER2 TIME pathology: Enable next generation TOMORROW dis

  12. Slide 12: Our diverse Oncology portfolio

    Our diverse Oncology portfolio AZD5863 (cLonis.2) AZD5854 (GPC3.CAR-T) Az06422 (CLDN18.2 CAR-T) NT-175 Sabestomig (7P53 RI7SH TCR-T) (Po-1/rIma) anaen NT-125 AZDOI71 TA) (multi-specific TERT) LiF) 8421 eae) 1PH5201 (cDK2) (PRMTS) (c033) AzD0486 (cbi9/cb3) Gco12F (cD19/BcMA CAR) 2 Volrustomig rastuzu

  13. Slide 13: Strengthening our portfolio through collaborations and agreements

    Strengthening our portfolio through collaborations and agreements Scorpion Therapeutics: Accelerating our cell therapy Expanding our antibody drug Drugging ‘undruggable’ transcription factors ambition conjugate (ADC) portfolio Chemical Proteomics Platform Novel TCE 80% ey neo/gene fZ0090% poten sin

  14. Slide 14: Redefining the backbone of current cancer treatment

    Redefining the backbone of current cancer treatment We are building ADCs which match disease biology, to enable combination therapies which induce deeper and more durable anti- tumour responses Targeting es Linker Payload ¥ YY Most patients receive chemotherapy, however significant toxicities remain

  15. Slide 15: Growing our portfolio of differentiated ADCs

    Growing our portfolio of differentiated ADCs 15 ~ G) Target and antibodies | _ Efficient delivery of antibody drug conjugate payload ¥ OED CIID Match disease biology and Optimize conjugation enable biology-driven chemistry and combinations to overcome potential off- a Ss overcome resistance target t

  16. Slide 16: AstraZeneca Targeted Delivery expertise complements Fusion opportunity

    AstraZeneca Targeted Delivery expertise complements Fusion opportunity for next-gen RC leadership Surface Proteomics (30349Ia ; o- om ot PB Arn ce00n, al Potten rrr Peptide VHH om Robust target discovery platform * Validated internal peptides and Leveraging linker expertise from ADC VHH hit discover

  17. Slide 17: We look forward to welcoming you to the team

  18. Slide 18: Social Media Posts

    Social Media Posts

  19. Slide 19: #AstraZenecaBusinessNews #Investors #Media

    #AstraZenecaBusinessNews #Investors #Media Intended for investors: Today we announced an agreement to acquire @Fusion Pharmaceuticals Inc., a biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major major step forward in our ambition to transform canc

  20. Slide 20: Thrilled to share that @AstraZeneca has announced

    Thrilled to share that @AstraZeneca has announced an agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). Radiotherapy plays an important role in cancer treatment for many patients, and together with Fusion we

  21. Slide 21: Today we announced an agreement to acquire Fusion

    Today we announced an agreement to acquire Fusion Phamaceuticals Inc., pioneers of next-generation #radioconjugates. This is an exciting opportunity to accelerate the development of this new modality with the potential to redefine radiotherapy in #oncology. At AstraZeneca we are relentless in our pu

  22. Slide 22: I'm excited to share that today at AstraZeneca

    I’m excited to share that today at AstraZeneca we announced an agreement to acquire Fusion Pharmaceuticals who are developing next-generation radioconjugates (RCs). The acquisition will build on our existing collaboration with Fusion. Throughout our collaboration I have been impressed by the talente

  23. Slide 23: Excited to share the fantastic news that at AstraZeneca

    Excited to share the fantastic news that at AstraZeneca we have announced an agreement to acquire Fusion Phamaceuticals. Radioconjugates (RCs) are gaining attention as a promising new modality in cancer treatment. By using targeting molecules to precisely deliver radioisotopes to cancer cells, RCs h

  24. Slide 24: Thrilled to share that AstraZeneca has announced

    Thrilled to share that AstraZeneca has announced an agreement to acquire Fusion Pharmaceuticals, accelerating our radioconjugate (RC) ambition. The acquisition is an exciting opportunity that will bring in Fusion’s best-in-class team, novel pipeline and extensive manufacturing and supply chain capab

Fusion Pharmaceuticals — Merger or Acquisition (March 2024) on 6ix